FDA tags Bay­er's prostate can­cer drug for pri­or­i­ty re­view as drug­mak­er gears up against ri­vals

Two months af­ter Bay­er and its Finnish part­ner Ori­on re­port­ed pos­i­tive late-stage da­ta for its prostate can­cer drug daro­lu­tamide, the Ger­man drug­mak­er has con­vinced the FDA to grant pri­or­i­ty re­view on its NDA.

Like Pfiz­er’s Xtan­di and J&J’s Er­lea­da, daro­lu­tamide is a non-steroidal an­dro­gen re­cep­tor in­hibitor for prostate can­cer pa­tients whose dis­ease has not spread but con­tin­ues to grow de­spite low testos­terone lev­els. But un­like the more en­trenched drugs — both billed as po­ten­tial block­busters — Bay­er says its drug has “in­her­ent­ly dif­fer­ent phar­ma­co­ki­net­ics,” lead­ing to less CNS tox­i­c­i­ty and low­er risk for drug-drug in­ter­ac­tions.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Life Sciences Senior Associate

General Catalyst

San Francisco, CA, USA